Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours
Year: 2003
Type: article
Study design: Clinical Trial
Source: European Journal of Cancer
Authors: F.A.L.M Eskens, H Dumez, R Hoekstra, A Perschl, C Brindley, S Böttcher, W Wynendaele, J Drevs, J Verweij, A.T van Oosterom
Language: English
Subfield: Immunology and Allergy
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2014825000